Clinical trial readout dates for NovoCure Limited, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is October 2028.
Next readoutOctober 2028in ~23 months
Upcoming readouts22 Phase 3
Market cap$2.1B
Cash & investments$97M~9 quarters at last loss rate
Recent 8-K filings2latest 2026-11-09
Upcoming readouts
Phase 3NovoTTF-200T
Metastatic Non-small Cell Lung Cancer · NCT06216301
NovoCure Limited reported $97M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $10M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.